Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) is a technology company with a robust patent portfolio for the improved delivery of bioactive compounds. An article entitled, “FDA Proposal Puts Spotlight on Big Tobacco and Industry Innovators”, highlights Lexaria’s exposure to nicotine as well as technology.
As quoted in the article:
Lexaria Bioscience’s intellectual property portfolio features a collection of advancements focused on improving the delivery and absorption of targeted molecules – such as nicotine – to the human body. Notably, the company maintains a patented method by which it is able to infuse a cocktail of molecules that are otherwise difficult for the body to absorb within other ingredients at a molecular level. As Lexaria’s website outlines, the company’s platform allows for the infusion of beneficial hemp oil ingredients into easily-absorbed lipids, greatly increasing the efficiency of absorption. Currently implemented in the production of two distinct consumer product brands including ViPova™ and Lexaria Energy, this technology has proven to be a potential game changer in the cannabinoid-based pharmaceuticals market, an industry that’s on course to grow to $50 billion by 2029, per data aggregated by Statista.